Isabelle Arnoux

Isabelle Arnoux

Auto-generated profile, based on publicly available information

Isabelle Arnoux

Center for Interdisciplinary Research in Biology, Collège de France, CNRS, INSERM, PSL-Neuro, Université PSL, Paris, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2012 in The Journal of Neuroscience
Verified
Journal Article
Open access
MHMaki Hoshiko
Maki Hoshiko
IAIsabelle Arnoux
Isabelle Arnoux
EAElena Avignone
Elena Avignone
NYNobuhiko Yamamoto
Nobuhiko Yamamoto
EAEtienne Audinat
Etienne Audinat
Accumulative evidence indicates that microglial cells influence the normal development of brain synapses. Yet, the mechanisms by which these immune cells target maturating synapses and influence their functional development at early postnatal stages remain poorly understood. Here, we analyzed the role of CX3CR1, a microglial receptor activated by the neuronal chemokine CX3CL1 (or fractalkine) which controls key functions of microglial cells. In the whisker-related barrel field of the mouse somatosensory cortex, we show that the recruitment of microglia to the sites where developing thalamocortical synapses are concentrated (i.e., the barrel centers) occurs only after postnatal day 5 and is controlled by the fractalkine/CX3CR1 signaling pathway. Indeed, at this developmental stage fractalkine is overexpressed within the barrels and CX3CR1 deficiency delays microglial cell recruitment into the barrel centers. Functional analysis of thalamocortical synapses shows that CX3CR1 deficiency also delays the functional maturation of postsynaptic glutamate receptors which normally occurs at these synapses between the first and second postnatal week. These results show that reciprocal interactions between neurons and microglial cells control the functional maturation of cortical synapses.

1 February 2017 in Progress in Neurobiology
Verified
Journal Article
Closed access
CMCoralie-Anne Mosser
Coralie-Anne Mosser
SBSofia Baptista
Sofia Baptista
IAIsabelle Arnoux
Isabelle Arnoux
EAEtienne Audinat
Etienne Audinat

1 January 2015 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
IAIsabelle Arnoux
Isabelle Arnoux
EAEtienne Audinat
Etienne Audinat
Microglial cells are the resident macrophages of the central nervous system (CNS). Besides their classical roles in pathological conditions, these immune cells also dynamically interact with neurons and influence their structure and function in physiological conditions. The neuronal chemokine fractalkine and its microglial receptor CX3CR1 are one important signaling pathway involved in these reciprocal interactions. In the present review, we will discuss recent evidence indicating that fractalkine signaling also determines several functions of microglial cells during normal CNS development. It has been known for a decade that microglial cells influence the neuronal death that normally occurs during CNS development. Surprisingly, recent evidence indicates that they can also support survival of developing neurons, control axon outgrowth, and laminar positioning of subsets of interneurons in the forebrain. Moreover, microglial cells influence the maturation of synaptic circuits at early postnatal stages: their phagocytic activity allows them to eliminate inappropriate synapses and they can also influence the functional expression of synaptic proteins by releasing mediators. Fractalkine signaling controls these functions of microglial cells in part by regulating their timely recruitment at sites of developing synapses. Finally, on-going research suggests that this signaling pathway is also a key player in neurodevelopmental disorders.

6 September 2013 in Cell Death & Differentiation
Verified
Journal Article
Closed access
MSM Á Carrillo-De Sauvage
M Á Carrillo-De Sauvage
LML Maatouk
L Maatouk
IAI Arnoux
I Arnoux
MPM Pasco
M Pasco
ADA Sanz Diez
A Sanz Diez
SVS Vyas
S Vyas

26 July 2013 in Glia
Verified
Journal Article
Closed access
PDF file
IAIsabelle Arnoux
Isabelle Arnoux
MHMaki Hoshiko
Maki Hoshiko
LMLéo Mandavy
Léo Mandavy
EAElena Avignone
Elena Avignone
NYNobuhiko Yamamoto
Nobuhiko Yamamoto
EAEtienne Audinat
Etienne Audinat

4 September 2018 in eLife
Verified
Journal Article
Open access
IAIsabelle Arnoux
Isabelle Arnoux
MWMichael Willam
Michael Willam
NGNadine Griesche
Nadine Griesche
JKJennifer Krummeich
Jennifer Krummeich
HWHirofumi Watari
Hirofumi Watari
ASAlbrecht Stroh
Albrecht Stroh
Catching primal functional changes in early, ‘very far from disease onset’ (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex - one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the antidiabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms.